GlaxoSmithKline plc, Aviva plc And Ryanair plc: 3 Shares To Buy Now

GlaxoSmithKline plc (LON: GSK), Aviva plc (LON: AV) and Ryanair plc (LON: RYA) are three shares to add to your Lifetime ISA.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I think George Osborne has delivered a great budget for investors. With him increasing the ISA allowance from £15,240 to £20,000 (as from April 2017), and cutting capital gains tax, it all means that investors will now have to pay far less tax on their shareholdings and that can only encourage investment.

And the fact that tax on buy-to-let has been increased makes buying stocks an even more attractive option for those who want to make the most of their savings. That’s why there has been no better time to start investing. And if you want to buy into the stock market, here are my three shares to start with right now.

GlaxoSmithKline

Big Pharma has tended to disappoint in recent years, as the patent cliff and increasing competition from generics has led to stagnant profits. Yet there’s no doubt that there’s an increasing market for medicines, as the world’s population increases, as it ages, as it gets more wealthy, and as the demand for treatments for ‘rich man’s’ diseases such as cancer, heart disease and diabetes grows.

The science base in this country, from large companies and SMEs to the universities, is one of the strongest in the world. GlaxoSmithKline (LSE: GSK) can feed off these many strengths to develop and market its treatments for a global marketplace. And it’s working towards this by expanding beyond the chemical drugs of the past into biotechnology, vaccines, consumer healthcare and HIV treatments.

With this potential in mind, a 2016 P/E ratio of 16.34 seems reasonable, and a dividend yield of 5.77% is appealing. Buy this for the income and for its long-term growth prospects.

Aviva

Insurance may not be a glamorous industry, but for investors in search of blue-chip income and growth, this has been a happy hunting ground. Global insurer Aviva (LSE: AV) is a case in point.

After going through a rocky patch in the years following the Credit Crunch, during which time the bloated insurance giant turned a loss and had to slash jobs, Aviva is now strongly profitable again. And it’s also yielding an impressive dividend. A 2016 P/E ratio of 10.50, and a 5.28% dividend yield make Aviva a strong buy, in my opinion.

Ryanair

Amidst the commodities crunch, with oil and mineral prices collapsing, and the shares prices of firms such as BP and BHP Billiton falling, one group of companies has (perhaps not surprisingly) emerged as winners from the turmoil: the airlines.

One airline that’s frequently overlooked as an investment is Ryanair (LSE: RYA). This company flies budget routes all across Europe, and is already benefitting from falling aviation fuel prices. Earnings per share have jumped from 39.47p in 2013 to 62.68p in 2015, and are expected to climb higher still. And a 2016 P/E ratio of 14.67 looks good value too.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Prabhat Sakya has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Is National Grid too boring for my Stocks and Shares ISA? 

Harvey Jones is looking for a solid FTSE 100 dividend growth stock for this year's Stocks and Shares ISA limit.…

Read more »

Investing Articles

Down 20% this month, can this struggling FTSE 100 stock recover?

Shares in delivery company Ocado are down considerably this month, continuing a multi-year trend. Is there still hope for this…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

2 FTSE 100 high dividend shares to consider in May

I'm building a list of the best FTSE 100 income shares to buy this month. Here are two I'm expecting…

Read more »

Ice cube tray filled with ice cubes and three loose ice cubes against dark wood.
Investing Articles

Just released: Share Advisor’s latest lower-risk, higher-yield recommendation [PREMIUM PICKS]

Ice ideas will usually offer a steadier flow of income and is likely to be a slower-moving but more stable…

Read more »

Investing Articles

Here’s how I’d target passive income from FTSE 250 stocks right now

Dividend stocks aren't the only ones we can use to try to build up some long-term income. No, I like…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

If I put £10k in this FTSE 100 stock, it could pay me a £1,800 second income over the next 2 years

A FTSE 100 stock is carrying a mammoth 10% dividend yield and this writer reckons it could contribute towards an…

Read more »

Investing Articles

2 UK shares I’d sell in May… if I owned them

Stephen Wright would be willing to part with a couple of UK shares – but only because others look like…

Read more »

Investing Articles

2 FTSE 250 shares investors should consider for a £1,260 passive income in 2024

Investing a lump sum in these FTSE 250 shares could yield a four-figure dividend income this year. Are they too…

Read more »